LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Spine/First Two Surgeries Performed Using Centinel Spine’s Midline II-Ti
Spine

First Two Surgeries Performed Using Centinel Spine’s Midline II-Ti

August 3, 2015 2 min read Premium comments

Advertisement

First Two Surgeries Performed Using Centinel Spine’s Midline II-Ti
Midline II-Ti/Centinel Spine, Inc.
Secondary

The first two surgeries using Centinel Spine, Inc.’s Midline II-Ti fusion device have been performed in Texas and Florida.

On July 28, 2015, the company announced that Jessica Shellock, M.D., Texas Back Institute, Plano. Texas, and James Billys, M.D., Florida Orthopaedic Institute, North Tampa, Florida, performed the surgeries.

Shellock said she was impressed with the, “simplicity of implantation, the immediate stability of the device and the visibility of the titanium coating on the postoperative imaging.” Billys said he has used Stalif ALIF implants for many years with, “excellent clinical outcomes as well as high fusion rates.” He said the Midline II has the same “easy placement as the PEEK cage with the added advantages of the titanium coating.”

Titanium Coating

The device is designed with Ti-Active, a multidimensional, texturized titanium coating engineered with over 15 years of science and experience to provide “primary stability with an optimized topography enabling cellular attachment and proliferation as observed in a preclinical analysis.” The device is a no-profile anterior lumbar system used to treat degenerative pathologies in the lumbar spine.

Features

Features of the device noted by the company on its website include:

  • Easier access to screw holes due to a medial screw placement which results in a 17% reduction of the overall surgical envelope as compared to Stalif Midline—ultimately providing for decreased tissue retraction.
  • Greater graft area due to an open center to promote fusion throughout, the graft containment area represents a 70% increase over Stalif Midline.
  • Maximized opportunities for fusion due to an increased anterior/posterior depth to achieve greater indirect decompression while concurrently sitting on the apophyseal ring. In addition, the company says it provides surgeons with the largest number of implant size offerings in the industry—ensuring patients are receiving the best anatomical fit possible.

The company introduced the fusion device at last year’s North American Spine Society meeting, claiming the Midline II is the “only Stand-Alone, No-Profile, Lumbar Integrated Interbody fusion device, with compressive fixation, that has been proven to be biomechanically equivalent to a 360° fusion.” The no-profile” design allows it to nest fully within the confines of the vertebral body, leaving the anatomy unchanged external to the interbody.

Centinel Spine President and CEO John Viscogliosi said the addition of the device to the company’s product portfolio, “is another step towards fulfilling Centinel Spine’s corporate mission of becoming the leader in anterior column support.”

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy